ReNeuron Group plc (LON:RENE – Get Free Report)’s share price fell 2.2% during trading on Thursday . The company traded as low as GBX 3.28 ($0.04) and last traded at GBX 3.38 ($0.04). 177,373 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 578,249 shares. The stock had previously closed at GBX 3.45 ($0.04).
ReNeuron Group Price Performance
The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25. The business’s 50-day simple moving average is GBX 3.38 and its two-hundred day simple moving average is GBX 3.38. The firm has a market cap of £1.93 million, a price-to-earnings ratio of -37.50 and a beta of 0.83.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Further Reading
- Five stocks we like better than ReNeuron Group
- Energy and Oil Stocks Explained
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- Consumer Discretionary Stocks Explained
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
